Excellence through Research and Development of Innovative Biotechnology
HA TECH is an Australian based Company, Developing & Delivering innovative Diagnostic and Pharmaceuticals products, focuses on the diagnosis of serious infectious diseases: respiratory Including COVID-19, sexually transmitted infection (STI) and mosquito-borne diseases that affect hundreds of millions of people worldwide and are among the most urgent global health challenges. The Company is making long-term investments to develop pharmaceutical products and medical technologies/ devices to address major health problem in Australia and globally.
CALL NOW AT
HA TECH Is Looking To Change The Industry Status Quo.
As members of the global healthcare community, HA TECH focuses on reducing the burden of disease with our products and development of novel technologies.
HA TECH aims to be inclusive and make diagnostic products that are accessible and only require basic laboratory equipment rather than restricting the use of kits to own brand equipment.
We value Science with our company run with an emphasis on researchers leading development.
HA Tech Board
Abdullah MahmudExecutive Chairman
Abdullah has more than 13 years’ work experiences across Europe, Australia and New Zealand. He acquired BEng (Hons) from University of Greenwich, UK; Post graduate studies from University of Surrey, UK; and Executive Business courses from City University of London.
He is the founder of HA Tech which he has started in 2017, Sydney based research and manufacturing of pharmaceutical active ingredients. He has held extensive leadership role in multiple organisation such as WSP| Parsons Brinckerhoff, HA Builders Pty Ltd and Maliha Pty Ltd. He has proven record in co-ordinating multi-disciplinary project teams. Also, prepare group’s annual budget, profit and loss statement. He has successfully led project co-ordination, project and proposal manager role for multiple projects. His business experience extends from Pharmaceuticals, Healthcare, Major infrastructure development, Residential development, Franchise and Retail.
Dr. Hani NurManaging Director
Hani Nur, A Biotech Industry Expert, joined HA TECH in 2019 as Managing Director. Dr Nur has extensive experience in developing and commercializing a wide range of healthcare products & technologies, in particular: IVD Medical Devices (In-Vitro Diagnostics)
and Fertility Medical Devices for Assisted Reproductive Technology (ART) such as In Vitro Fertilisation (IVF). In addition to corporate, portfolio & growth strategy, she has significant working experience under a range of regulatory environments across ISO 9001 & 13485, and experience with QMS development / maintenance in product/process development, validation, manufacturing, Quality Assurance and Regulatory Affairs. Prior to joining HA TECH, Dr Nur worked as a Lead Scientist at the bio-separation company NuSep (currently Memphasys) at Sydney, Australia. At NuSep, she led multiple projects with team of varying sizes for several innovative bio-separation applications and patented the novel findings which include: long-life Polyacrylamide electrophoresis Gels for the separation of Proteins and DNA, Hydrogel Membranes for a Human Plasma Fractionation device to isolate high value proteins such as Albumin and Immunoglobulin (IgG) for therapeutic applications and Biocompatible Membranes for human ART Medical Devices to isolate healthy sperm cells for fertility treatments such as IVF.
Professor Martin SnowdenPhD, CSci, CChem, FRSC, PFHEA (UK)
Prof. Martin Snowden is Pro Vice-chancellor and head of the Faculty of Engineering and Science at the University of Greenwich in London, UK. He has a distinguished track record of high-quality published output including the publication of
17 Q1 Pharmaceutical Science papers since 2014 (h-index 41). Professor Snowden is a Principal Fellow of the Higher Education Academy and an Eminent Fellow of the Academy of Pharmaceutical Sciences. He provides strategic leadership for all the International work of the University including its very successful Trans National Education provision. He also provides leadership and strategic development to 4 major academic disciplines including Engineering, Pharmacy, Science and the Natural Resources Institute. Professor Snowden has many successful partnerships with leading Pharmaceutical companies including Pfizer and GSK
Professor Fariba DehghaniPhD (University of New South Wales, Australia)
Professor Fariba Dehghani is currently the director of Centre for Advanced Food Engineering and a former director of an ARC Food Processing Training Centre at the University of Sydney, Australia. She was recognised by Engineers Australia as one of the Australian’s
top 50 Engineers for innovation. Her research team collaborated with industry to provide pragmatic, cost-effective and environmentally sustainable solutions to a diverse range of issues, with the aim of improving human wellbeing. After completion of her PhD degree at UNSW, she received the prestigious Australian Research Council Postdoctoral fellowship and continued working at UNSW as a senior research fellow and senior lecturer. She played a major role in the establishment of a R&D Company with Good Manufacturing Practice (GMP) facility and developed technologies and products that were sub-licensed to industries. Since joining the University of Sydney in 2006, she established a state-of-the-art bioengineering laboratory enabling multidisciplinary research collaboration. She promotes entrepreneurial engagement, resulting in four start-up companies being established by her research members. The focus of her current research is on developing biomaterials for medical devices, biosensors and nutraceuticals and food for promoting human health and environmental sustainability.
Dr Peter ValtchevPhD (University of Sydney, Australia)
Dr. Valtchev works in the department of Chemical and Biomolecular Engineering at the University of Sydney and has extensive experience in the fields of drug discovery and drug development, drug delivery, tissue engineering, therapeutic drug monitoring, metabolism and pharmacokinetics
He has more than 50 publications, 4 patents and his H-index is 18 reflecting work on multi-disciplinary projects involving therapeutic proteins, natural bioactive compounds, tissue scaffolds and drug delivery devices. Peter has more than 10 years of experience in the pharmaceutical and clinical diagnostics industry.
Ross William BriertyInternational Marketing Executive
He has more than 25 years of experience working in more than 25 countries within the global Healthcare, Laboratory and Biotechnology sectors. He has held senior management and executive positions in Australia and North America, with responsibility for the new business, strategy, development
and commercialisation of products and start-ups. Highlights of his career include working as Chief Executive Officer of AgriGen Biotech where he expanded the business operations throughout Asia including sites in India, Bangladesh, Thailand, Vietnam, Brunei, Malaysia, Indonesia and China. AgriGen has experienced rapid expansion of its off-shore due to demand of its unique analytical testing platform and the systems. Ross holds a Bachelor of Science from Monash University (Biochemistry & Pharma- cology) and a Master of Business Administration from Victoria University. He is an APEC Card holder, Member of the Melbourne Cricket Club Member.
Dr Mike RichardsonPhD (ANU, Australia)
Dr. Richardson has worked in the Biotechnology/Health Care Industry for more than 30 years. After finishing a Postdoctoral Fellowship at the Roche Institute of Molecular Biology (Nutley, New Jersey) Dr. Richardson spent 2 years
at the Nippon Roche Research Center (Kamakurra, Japan) before joining Biotech Australia in Sydney, Australia. In his role at Biotech Australia Dr. Richardson engineered bacterial, yeast, insect and mammalian cell systems to produce recombinant and non-recombinant proteins for ‘in-vitro’, animal and human trials of potential therapeutic treatments. As Director of Science at Isolagen Australia Dr. Richardson was involved in the production, QC, QA, and release for sale of a TGA licensed product (under the TGA cGMP code for ‘Human Blood and Tissue). At NuSep (Sydney, Australia), Dr. Richardson developed In vitro diagnostic (IVD) reagents (for the detection of Lupus and von Willebrand diseases) for sale in the Australian market. Later, as Operations Manager, he was responsible for the production of pre-cast polyacrylamide gels sold worldwide
Prof. Shariff Enamul KabirPhD (University College London, UK)
Prof. Kabir has been actively involved in research for the last 37 years in diverse field of chemistry. His research findings have shown direct applications in developing models of more complex polynuclear metal sites present in
heterogeneous catalytic systems. His innovative research that he has pioneered is utilized by industries to remove sulfur from organosulfur compounds present in petroleum-based feedstock which is crucial both environmentally and commercially. More recently, Prof. Kabir, in collaboration with Khan’s group of Bangladesh Atomic Energy Commission, has focused his attention towards developing natural and synthetic polymer blend composites. These elegant studies proved that the eco-friendly bio-degradable packaging material based on natural and synthetic polymers may be a good replacement of conventional synthetic packaging material. Prof. Kabir has built an active research group in organometallic cluster chemistry and bioinorganic chemistry in the department of chemistry at Jahangirnagar University. So far twenty-five Ph. D. and three M. Phil. students successfully obtained respective degrees under his supervision. Currently, fifteen M. Sc., M. Phil. and Ph. D. students are working on the various aspects of cluster chemistry and bioinorganic chemistry. Prof. Kabir presently holds and has held many strong administrative positions: Member Bangladesh Public Service Commission (2012- 2017); Vice-Chancellor (2009-2012), Treasurer (1998-2001), Chairman (2007-2009), Senate member (1998-present), and Syndicate member (2015-present) at Jahangirnagar University, Dhaka, Bangladesh He has maintained academic appointment, positions and research collaboration with number of universities worldwide includes University College London, UK; California State University Northridge, USA; University of Montana, USA; Freiburg University, Germany and Lund University, Sweden. He has published 324 research papers in prestigious Journals and reviewer of reputed International and National Journals. He has also made distinct contributions in mentoring young colleagues and scientists by fostering diversity and developing research facilities. Many students trained in his laboratory are currently working in various research institutions, industries and universities within the country and abroad successfully